Pharsight

1. List of Incruse Ellipta drug patents

Application	Filing Date	Opposition Party	Legal Status
EP06765149A	2020-04-17	ELKINGTON AND FIFE LLP	Patent maintained as amended

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7498440	GLAXO GRP ENGLAND	Muscarinic acetylcholine receptor antagonists	Apr, 2025 (2 years from now)
US7488827	GLAXO GRP ENGLAND	Muscarinic acetylcholine receptor antagonists	Dec, 2027 (4 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8309572	GLAXO GRP ENGLAND	Muscarinic acetylcholine receptor antagonists	Apr, 2025 (2 years from now)
US8183257	GLAXO GRP ENGLAND	Muscarinic acetylcholine receptor antagonists	Jul, 2025 (2 years from now)
US9333310	GLAXO GRP ENGLAND	Medicament dispenser	Oct, 2027 (4 years from now)
US8113199	GLAXO GRP ENGLAND	Counter for use with a medicament dispenser	Oct, 2027 (4 years from now)
US8161968	GLAXO GRP ENGLAND	Medicament dispenser	Feb, 2028 (4 years from now)
US8201556	GLAXO GRP ENGLAND	Medicament dispenser	Feb, 2029 (5 years from now)
US8534281	GLAXO GRP ENGLAND	Manifold for use in medicament dispenser	Mar, 2030 (6 years from now)
US8746242	GLAXO GRP ENGLAND	Medicament dispenser	Oct, 2030 (7 years from now)

Exclusivity	Exclusivity Expiration
M (M)	Jun 9, 2022

Market Authorisation Date: 30 April, 2014

Treatment: Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema.

Dosage: POWDER;INHALATION